(NASDAQ: CLGN) Collplant Biotechnologies's forecast annual revenue growth rate of 286.74% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Collplant Biotechnologies's revenue in 2025 is $515,000.On average, 1 Wall Street analysts forecast CLGN's revenue for 2026 to be $248,448,365, with the lowest CLGN revenue forecast at $248,448,365, and the highest CLGN revenue forecast at $248,448,365. On average, 1 Wall Street analysts forecast CLGN's revenue for 2027 to be $343,291,725, with the lowest CLGN revenue forecast at $343,291,725, and the highest CLGN revenue forecast at $343,291,725.
In 2028, CLGN is forecast to generate $340,199,006 in revenue, with the lowest revenue forecast at $340,199,006 and the highest revenue forecast at $340,199,006.